Zacks Projects $15B AGI CPU Revenue by FY31, But Supply and Valuation Risks Loom

What happened

Zacks Investment Research released a new estimate that Arm's AGI CPU could unlock about $15 billion in revenues by fiscal 2031, with meaningful sales beginning in fiscal 2028. The projection assumes no negative impact on Arm's existing IP licensing and CSS businesses, implying the new silicon effort is additive rather than cannibalistic. However, the DeepValue master report notes that Arm's current valuation already discounts strong execution, with the stock trading at roughly 295.5x earnings and 215.9x EV/EBITDA. Near-term supply constraints have kept management's AGI CPU outlook capped at $1 billion despite visible demand exceeding $2 billion, with first revenue not expected until the fourth quarter of fiscal 2027. The divergence between long-term optimism and near-term execution risk leaves the risk-reward balanced, supporting a wait-and-see stance rather than aggressive buying at current levels.

Implication

The $15B FY2031 revenue projection is an aggressive long-term scenario that would require Arm to successfully scale production silicon, but it remains contingent on resolving supply-chain bottlenecks that currently cap the near-term outlook. While the article suggests no cannibalization of IP and CSS revenues, investors should monitor whether Arm's move into production silicon changes customer dynamics or margins, as the 20-F already flags different margin profiles and working capital needs. With the stock at ~$286 and trading at extreme multiples, the market is already pricing in substantial AI upside, leaving little room for error if AGI CPU revenue slips beyond the expected FQ4 FY2027 start. Key checkpoints remain the November 2026 and February 2027 earnings reports, where management must reaffirm ~20% royalty growth and provide clearer visibility on AGI CPU supply and shipments. Until those checkpoints are passed, maintaining a wait-and-see approach with an attractive entry near $220 or a reassessment after proof of execution is prudent, rather than chasing the stock on long-dated revenue hopes.

Thesis delta

The new Zacks projection adds a bullish long-term data point but does not alter the near-term thesis; the key swing factor remains whether Arm can convert supply-constrained AGI CPU demand into recognized revenue on schedule. The master report's WAIT rating stands, as the $15B FY31 revenue potential is already partially embedded in the stock's premium valuation and does not offset the lack of a margin of safety at current prices.